Loading clinical trials...
Loading clinical trials...
A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.
Conditions
Interventions
Placebo
AZD5634
Locations
3
United States
Research Site
Birmingham, Alabama, United States
Research Site
Baltimore, Maryland, United States
Research Site
Chapel Hill, North Carolina, United States
Start Date
May 30, 2017
Primary Completion Date
April 12, 2018
Completion Date
April 12, 2018
Last Updated
July 13, 2018
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions